Head to Head Contrast: Syndax Pharmaceuticals (SNDX) vs. Its Rivals

Syndax Pharmaceuticals (NASDAQ:SNDX) is one of 846 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Syndax Pharmaceuticals to related businesses based on the strength of its institutional ownership, valuation, dividends, profitability, earnings, risk and analyst recommendations.

Risk and Volatility

Syndax Pharmaceuticals has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals’ rivals have a beta of 1.14, suggesting that their average share price is 14% more volatile than the S&P 500.

Profitability

This table compares Syndax Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-72.32%	-804.38%	-34.93%
Syndax Pharmaceuticals Competitors	-12,285.98%	-196.04%	-30.61%

Earnings & Valuation

This table compares Syndax Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Syndax Pharmaceuticals	$289.68 million	-$285.42 million	-4.13
Syndax Pharmaceuticals Competitors	$729.47 million	$11.46 million	-14.96

Syndax Pharmaceuticals’ rivals have higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Syndax Pharmaceuticals and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1	0	10	0	2.82
Syndax Pharmaceuticals Competitors	9904	15278	45629	1595	2.54

Syndax Pharmaceuticals currently has a consensus target price of $41.60, suggesting a potential upside of 327.10%. As a group, “Biotechnology” companies have a potential upside of 120.67%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Syndax Pharmaceuticals is more favorable than its rivals.

Insider and Institutional Ownership

47.7% of shares of all “Biotechnology” companies are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Syndax Pharmaceuticals rivals beat Syndax Pharmaceuticals on 8 of the 13 factors compared.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R). The company’s medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation.